End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.48 CAD | +1.05% |
|
-4.00% | -1.03% |
06-05 | LSL Pharma to Raise $4.5 Million Via Private Placements | MT |
06-05 | LSL Pharma Group Inc. announced that it expects to receive CAD 3 million in funding | CI |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net sales 1 | 10.05 | 8.771 | 8.214 |
EBITDA 1 | 2.513 | 0.1023 | -5.838 |
EBIT 1 | 1.682 | -0.7078 | -6.758 |
Operating Margin | 16.74% | -8.07% | -82.27% |
Earnings before Tax (EBT) 1 | 0.8232 | -1.629 | -8.062 |
Net income 1 | 0.6099 | -1.777 | -8.062 |
Net margin | 6.07% | -20.26% | -98.15% |
EPS 2 | 0.0111 | -0.0299 | -0.1213 |
Free Cash Flow | - | -3.626 | 0.1085 |
FCF margin | - | -41.34% | 1.32% |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 30/12/22 | 30/12/22 | 08/05/23 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net Debt 1 | 8.64 | 12 | 12.7 |
Net Cash position 1 | - | - | - |
Leverage (Debt/EBITDA) | 3.439 x | 117.3 x | -2.173 x |
Free Cash Flow | - | -3.63 | 0.11 |
ROE (net income / shareholders' equity) | - | -16.6% | -96.2% |
ROA (Net income/ Total Assets) | - | -1.57% | -15% |
Assets 1 | - | 112.9 | 53.78 |
Book Value Per Share 2 | 0.1900 | 0.1800 | 0.0800 |
Cash Flow per Share 2 | 0.0400 | 0.0100 | - |
Capex 1 | 3.3 | 0.91 | 1 |
Capex / Sales | 32.88% | 10.43% | 12.14% |
Announcement Date | 30/12/22 | 30/12/22 | 08/05/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-1.03% | 37.79M | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- LSL Stock
- Financials LSL Pharma Group Inc.